Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 10.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 56,307 shares of the company's stock after purchasing an additional 5,400 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.'s holdings in Hims & Hers Health were worth $1,664,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. UMB Bank n.a. lifted its position in Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after acquiring an additional 933 shares during the period. Larson Financial Group LLC lifted its position in Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after acquiring an additional 458 shares during the period. Tsfg LLC acquired a new stake in Hims & Hers Health during the 1st quarter worth approximately $46,000. Fifth Third Bancorp lifted its position in Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after acquiring an additional 961 shares during the period. Finally, N.E.W. Advisory Services LLC acquired a new stake in Hims & Hers Health during the 1st quarter worth approximately $49,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares of the company's stock, valued at $2,987,239.50. This trade represents a 26.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the firm's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares of the company's stock, valued at $112,023,016.02. The trade was a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,460,276 shares of company stock valued at $77,374,454 in the last ninety days. Corporate insiders own 17.71% of the company's stock.

Analyst Ratings Changes

HIMS has been the subject of a number of recent research reports. Bank of America increased their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus target price of $39.83.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $47.88 on Wednesday. The company has a 50-day simple moving average of $53.39 and a 200-day simple moving average of $45.30. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $10.72 billion, a PE ratio of 59.85, a P/E/G ratio of 3.16 and a beta of 2.08. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. During the same period in the previous year, the business earned $0.06 earnings per share. The business's revenue for the quarter was up 72.6% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.